Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744701 | 1.00 | HCAR2 (0.47) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL9744705 | 1.00 | HCAR2 (0.47) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL14363086 | 1.00 | HCAR2 (0.47) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL1581950 | 1.00 | HCAR2 (0.47) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL425749 | 0.98 | HCAR2 (0.48) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL425748 | 0.98 | HCAR2 (0.48) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL1126533 | 0.94 | HCAR2 (0.48) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL1126534 | 0.94 | HCAR2 (0.48) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL587678 | 0.91 | HCAR2 (0.43) | HCAR2L3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL7512241 | 0.90 | HCAR2 (0.52) | HCAR2L3MBTL1LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-8975269-B2 | Six-membered N-heterocyclic carbene-based catalysts for asymmetric reactions | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140336402-A1 | LIGAND FORMING ASYMMETRICAL TRANSFORMATION CATALYST FOR MAKING NEW PHARMACEUTICALS | NATIONAL SCIENCE FOUNDATION | 2014-11-13 | — | — | US | disclosed |
| US-8822483-B2 | Six-membered N-heterocyclic carbene-based catalysts for asymmetric reactions | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004009536-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2004-01-29 | — | — | WO | disclosed |
| US-5621133-A | PREPARING A 1-(3,4-DIALKOXYPHENYL),3-HYDROXYALKANE(C6-C12) BY EPOXIDIZING A HALO DERIVATIVE WITH A BASE FOLLOWED BY DECYCLICIZING WITH AN ORGANOMETALLIC COMPOUND IN A SOLVENT; NAPHTHYLENES, ISOCHROMENES AND ISOTHIOCHROMENES | DENINNO MICHAEL P (US) | 1997-04-15 | — | — | US | disclosed |
| US-5591884-A | PROTECTED HYDROXYALKYLCATECHOL INTERMEDIATES | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996038435-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0474767-A4 | DOPAMINE AGONISTS | — | 1992-07-08 | — | — | EP | disclosed |
| EP-0474767-A1 | DOPAMINE AGONISTS. | ABBOTT LAB (US) | 1992-03-18 | — | — | EP | disclosed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | disclosed |
| US-4963568-A | TREATMENT OF PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | HCAR2 2864/4885L3MBTL1 2890/4885LMNA 2016/4885 |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | HCAR2 2864/4885L3MBTL1 2890/4885LMNA 2016/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | HCAR2 2587/4885L3MBTL1 2996/4885LMNA 2720/4885 |
| US-20140336402-A1 | LIGAND FORMING ASYMMETRICAL TRANSFORMATION CATALYST FOR MAKING NEW PHARMACEUTICALS | CYP3A4, CYP3A5, CYP2C18 | HCAR2 249/4885L3MBTL1 4662/4885LMNA 4687/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | HCAR2 2864/4885L3MBTL1 2890/4885LMNA 2016/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | HCAR2 3926/4885L3MBTL1 3062/4885LMNA 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.